Cramer's 'Mad Money' Recap: Backed Up Against a Wall of Shame

Biotech companies with pending drug approvals are always speculative, he said, and BioMarin is no different. If Kuvan doesn't get approval, the stock will get hurt badly. But it should get FDA approval by the end of the year, Cramer said.

He said people should consider buying BioMarin for Kuvan because if approved the stock will go much higher. At the same time, it is a risky investment, Cramer warned.

Who Will Take Us to Dow 14,548?

In his "Game Plan" segment, Cramer told viewers the Dow needs to go up by 653 more points to reach his year-end price target of 14,548.

He came to 14,548, Cramer said by doing a bottoms-up analysis of the Dow stocks. Some of the stocks, like Exxon Mobil (XOM Quote), Verizon (VZ Quote), General Motors (GM Quote) and Procter & Gamble (PG Quote), said Cramer, already have exceeded his price targets, and will probably go higher.

Other stocks like McDonald's (MCD Quote), Alcoa (AA Quote), Coca-Cola (KO Quote) and Merck (MRK Quote) are all trading around his individualized targets, he said.

But some stocks, like Wal-Mart (WMT Quote), Home Depot (HD Quote), Pfizer (PFE Quote) and Johnson & Johnson (JNJ Quote), Cramer expects, will do nothing.

When it comes down to it, Cramer said he believes four names will lead the charge to his target: Boeing (BA Quote), DuPont (DD Quote), Caterpillar (CAT Quote) and Altria (MO Quote), the latter two of which he owns for his charitable trust, Action Alerts PLUS.